A month after announcing the withdrawal from its Phase 3 Alzheimer’s trials, biopharma firm Biogen (NASDAQ: BIIB) on Wednesday reported first-quarter earnings
Spinraza helps Biogen beat the street in Q1
Categories
pharma stocks
Biocept narrows loss in Q4
Biocept (BIOC) narrowed its loss in the fourth quarter, beating analyst estimates. However, sales failed to impress the street. Shares of the
Why Amarin stock is rallying today
Amarin Corporation (NASDAQ: AMRN) shares got a major boost during the pre-market hours of Thursday after it said the American Diabetes Association
Earnings preview: What’s on the cards for Biocept in Q4
Biocept (BIOC) is scheduled to report fourth quarter and full year 2018 results on March 28, Thursday, after the regular trading hours.
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped
Onconova Therapeutics cuts down losses in 2018
Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in fiscal 2018
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Novavax misses Q4 estimates, shares slip
NVAX Earnings Transcripts NVAX Earnings Calendar Clinical-stage vaccine company Novavax (NVAX) reported a loss of 13 per share in the fourth
Earnings: Trevena slips on wider-than-expected Q4 loss
Trevena Inc (TRVN) Wednesday reported fourth-quarter losses that were wider than analysts’ estimates, sending its shares down 5.4% during pre-market trading. Helped
Portola Pharmaceuticals rises on strong Q4 earnings
Shares of Portola Pharmaceuticals (PTLA) gained 5.6% during pre-market trading on Friday, after the company posted a loss of $1.04 per share,
Amarin shares jump 14% on rumors over Novartis interest
Shares of Amarin Corp (AMRN) gained up to 14% during the regular trading hours on Friday as rumors of an acquisition once
CVS Health Q4 earnings preview: What to expect
CVS Health Corporation (CVS) is scheduled to report fourth-quarter earnings results before the regular trading hours on Wednesday, February 20. The retail
Earnings: Oncology unit drives AstraZeneca topline higher in Q4
AstraZeneca Plc (AZN) reported a 22% dip in earnings for the fourth quarter to 82 cents per share, weighed down higher costs.
Gilead’s credibility takes a hit on massive NASH-drug failure, rivals jump
Shares of Gilead Sciences (GILD) have tumbled 20% in the past 52 weeks on numerous reasons including weaker-than-expected quarterly results and a
Earnings: Array BioPharma delivers strong Q2 results, investors cheer
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million
Earnings: Pfizer edges past Q4 estimates, shares dip on weak outlook
Pfizer (PFE) reported a better-than-expected 2% increase in fourth-quarter revenues to $13.9 billion. Earnings rose to 64 cents per share from 62
Bristol-Myers Squibb reports Q4 earnings on Jan 24. What to expect
Only two weeks after announcing its massive acquisition of Celgene Corporation, drug-maker Bristol-Myers Squibb (BMY) is all set to report fourth-quarter results
Why Ligand Pharma, Viking Therapeutics tumbled yesterday, but is gaining today
Shares of Ligand Pharmaceuticals (LGND) took a beating on Wednesday after a bearish report by Citron Research led by short-seller Andrew Left
In a massive deal, Eli Lilly acquires Loxo Oncology
Eli Lilly and Company (LLY) on Monday announced that it would acquire a small biopharmaceutical startup that develops cancer treatment, Loxo Oncology
Johnson & Johnson dips on revenue decline in India
Johnson & Johnson (JNJ) shares fell 1% on Thursday after the company reported a 3% sales dip in India in the year
Johnson & Johnson will spend more time in court in 2019
The tainted talc has been snowballing into a gigantic threat since 2016, and things are not looking good as Johnson & Johnson